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Abstract
Boron neutron capture therapy (BNCT) is a radiotherapy that has mainly been used to treat
malignant brain tumours, melanomas, and head and neck cancer. In BNCT, the patient
receives an intravenous infusion of a 10B carrier, which accumulates in the tumour area.
The tumour is irradiated with epithermal or thermal neutrons, which result in a boron
neutron capture reaction 10B(n,a)7Li. This generates heavy particles that damage tumour
cells. In Finland, boronophenylalanine fructose (BPA-F) is used as the 10B-carrier. The
boron neutron capture reaction is responsible for the main therapeutic dose in BNCT, and
therefore all information about boron accumulation in the tumour area is valuable.
Currently, the drifting of boron from blood to tumour as well as the spatial and temporal
accumulation of boron in the brain, are not precisely known. The BNCT treatment
planning in Finland is based on estimations of boron concentrations in tumour and normal
brain. These concentratins, in turn, are based on whole blood boron concentration, and
assumption of constant boron concentration ratios for blood-to-tumour (1:3.5) and blood-
to-normal brain (1:1). During the irradiation, the whole blood boron concentration is
estimated with kinetic models from the whole blood boron concentrations of previously
collected periodic blood samples, where boron concentration is determined with
inductively coupled plasma-atomic emission spectrometry (ICP-AES). However, using
these constant concentration ratios of blood-to-tumour or blood-to-normal brain produces
significant uncertainties in estimating of the boron concentration in the normal brain and
tumour. Therefore, new methods would be needed to determine the boron concentration in
the brain non-invasively. Proton magnetic resonance spectroscopy (1H MRS) could be
used for selective BPA-F detection and quantification as aromatic protons of BPA
resonate in the spectral region, which is clear of brain metabolite signals.
This study, which included both phantom and in vivo studies, examined the validity of
MRS as a tool for BPA detection. In the phantom study, BPA quantification was studied at
1.5 and 3.0 T with single voxel 1H MRS, and at 1.5 T with magnetic resonance imaging
(MRSI). The J-modulation of a coupled spin system of BPA aromatic protons complicates
the determination of transverse relaxation time as well as the intensity measurement of the
BPA signal when uncoupled resonance is used as the concentration reference. Therefore,
the response curve of aromatic protons to the PRESS sequence was calculated and the
results were used for T2 determination and intensity corrections. The detection limit of
BPA was determined in phantom conditions at 1.5 T and 3.0 T with two different voxel
4sizes using single voxel 1H  MRS,  and  at  1.5  T  using  MRSI.  The  gross  tumour  volume
(GTV) may contain  a  resection  cavity  with  clotted  blood.  The  adverse  effects  of  clotted
blood on MRS were demonstrated with whole blood and blood plasma phantoms doped
with  BPA-F.  In  phantom conditions,  BPA quantification  accuracies  of  ±  5% and ±  15%
were achieved with single voxel MRS using external or internal (internal water signal)
concentration references, respectively. For MRSI, a quantification accuracy of <5% was
obtained using an internal concentration reference (creatine). The detection limits of BPA
in phantom conditions for the PRESS sequence were 0.7 (3.0 T) and 1.4 mM (1.5 T) with
203 mm3 single voxel MRS, 1.4 (3.0 T) and 2.2 mM (1.5 T) with 1.53 mm3 single voxel
MRS, and 1.0 mM with acquisition-weighted MRSI (nominal voxel volume 10(RL) ×
10(AP) × 7.5(SI) mm3), respectively. The blood-originated interference was prominent in
the whole blood/BPA-F spectrum, indicating that there are many challenges to BPA
detection in in vivo conditions, such as susceptibility effects caused by clotted blood in the
resection cavities of operated tumours.
In the in vivo study,  an  MRSI  or  single  voxel  MRS  or  both  were  performed  for  ten
patients (patients 1-10) on the day of BNCT. Three patients had glioblastoma multiforme
(GBM), and five patients had a recurrent or progressing GBM or anaplastic astrocytoma
gradus III, and two patients had head and neck cancer. For nine patients (patients 1-9),
MRS/MRSI was performed 70-140 min after the second irradiation field, and for one
patient (patient 10), the MRSI study began 11 min before the end of the BPA-F infusion
and ended 6 min after the end of the infusion. In comparison, single voxel MRS was
performed before BNCT, for two patients (patients 3 and 9), and for one patient (patient
9),  MRSI  was  performed one  month  after  treatment.  For  one  patient  (patient  10),  MRSI
was performed four days before infusion. Signals in the tumour spectrum aromatic region
were detected on the day of BNCT in three patients, indicating that in favourable cases, it
is possible to detect BPA in vivo in the patient’s brain after BNCT treatment or at the end
of BPA-F infusion. However, because the shape and position of the detected signals did
not exactly match the BPA spectrum detected in the in vitro conditions, unambiguous
assignment of BPA is difficult. The opportunity to perform MRS immediately after the
end of BPA-F infusion for more patients is necessary to evaluate the suitability of 1H MRS
for BPA detection or quantification for treatment planning purposes. However, it could be
possible to use MRSI as criteria in selecting patients for BNCT.
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8Abbreviations
BNCT  Boron neutron capture therapy
BPA-F  Boronophenylalanine-fructose
BSH  Sodium borocaptate
CHESS  Chemical shift selective imaging
Cho Choline
DEFT  Driven equilibrium Fourier transform
FOV  Field of view
FWHM Full width at half maximum
Glc Glucose
Gln Glutamine
Glu Glutamate
Glx Glutamate plus glutamine
GTV  Gross tumour volume
ICP-AES Inductively coupled plasma-atomic emission spectrometer
ICRU  International Commission of Radiation Units and Measurements
IR Inversion recovery
ISIS  Image Selected In Vivo Spectroscopy
Lac Lactate
LASER  Localisation by Adiabatic Selective Refocusing
mI Myo-inositol
MM Macromolecule
MRI Magnetic resonance imaging
MRS  Magnetic resonance spectroscopy
MRSI Magnetic resonance spectroscopy imaging
NAA N-acetylaspartate
NMR Nuclear magnetic resonance
NRG  Nuclear research & consultancy group
PEPSI  Proton echo planar spectroscopic imaging
PET  Positron emission tomography
ppm  Parts per million
PRESS  Point Resolved Spectroscopy
PSF Point spread function
PGS  Prompt gamma spectroscopy
SE Spin echo
sI Scyllo-Inositol
SLIM Spectral localisation by imaging
SLOOP Spectral localisation with optimal pointspread function
SNR Signal-to-noise ratio
STEAM  Stimulated echo acquisition mode
tCr Total creatine (creatine + phoshpocreatine)
TE Time of echo
9TM Mixing time
TR Time of repetition
TSI Turbo spectroscopic imaging
VOI  Volume of interest
WEFT  Water eliminated Fourier transform
In this work, the abbreviation ppm (parts per million) has been used in two different
contexts. The chemical shift is expressed in units of ppm, as it is independent of the
magnetic field strength used. In addition, the whole blood boron concentration is
expressed in ppm (mg/kg) instead of mg/L, or mmol/L, as is the widespread practice
among the BNCT community.
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1. INTRODUCTION
1.1. Boron neutron capture therapy
Boron neutron capture therapy (BNCT) is a bimodal radiotherapy that has traditionally
been  used  to  treat  malignant  brain  tumours  and  melanomas  (Diaz et al. 2000). In recent
years, BNCT has also been used to treat recurring head and neck carcinoma with good
response (Kankaanranta et al. 2007, Kato et al. 2004, Kouri et al. 2004). In BNCT, the
patient receives an intravenous infusion of a 10B carrier compound. As a result, boron
accumulates in the tumour area. After an appropriate time interval, when the boron
concentration in the tumour area has increased sufficiently relative to the surrounding
healthy tissue, the tumour is irradiated with epithermal or thermal neutrons. The boron
neutron capture reaction 10B(n, a)7Li generates heavy particles that damage the tumour
cells. The idea of clinical BNCT was illustrated for the first time in 1936 (Locher). The
first pioneering trials of BNCT were performed in the USA during 1951-1961 with
unsatisfactory treatment results and adverse effects (Busse et al. 2001). The major reason
for the disapointing results of the very first BNCT trials was the use of inadequate boron-
carrier compounds and undeveloped thermal neutron generating facilities (Busse et al.
2001). Subsequent trials in Japan were more promising (Nakagawa 2001). Clinical trials
began again in Europe and the US in late 1980s with boronophenylalaline (BPA) and
sodium borocaptate (BSH) as boron carriers. In Finland, clinical trials began in 1999
(Joensuu et al. 2003) with boronphenylalanine fructose (BPA-F).
The boron neutron capture reaction is responsible for the main therapeutic dose in
BNCT, but the total biological effect is the sum of all dose components. The thermal
neutrons also react with hydrogen 1H(n,?)2H and nitrogen 14N(n,p)14C*  in  the  tissue,
producing a significant partion of the total patient dose. In addition, the reactor produces
fast  neutrons  and  gamma  radiation  with  an  energy  range  of  0-15  MeV.  To  estimate  the
biological response of the tissue to the combination of all these doses, the concept of
weighted dose is used. The total biologically weighted dose DW is a sum of physical dose
components (Di) multiplied by weighting factors (wi) of each dose component in a tissue.
The biologically weighted dose can be written (IAEA 2001):
(1) DW= wgDg + wBDB + wNDN + wnDn,
where Dg is the gamma dose, DB the boron capture dose, DN the nitrogen capture dose
and Dn the dose from epithermal and fast neutrons. The unit for the biologically weighted
total  dose  is  Gy  (W)  where  the  W  in  parenthesis  is  used  to  emphasise  the  weighting
whereas the physical dose components are expressed in Gy unit. Detailed physical
quantities for BNCT dosimetry have previously been presented in doctoral theses by A.
Kosunen (1999), M. Kortesniemi (2002), P. Ryynänen (2002), T. Seppälä (2002), P.
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Kotiluoto (2007) and J. Uusi-Simola (2009). The weighted boron dose was approximately
90% of the total weighted dose for a tumour and 45% for a  normal  brain  at  the  dose
maximum, according to a sample BNCT dose plan presented in the thesis by Seppälä
(2002). The average planning target volume doses varied from 25 to 61 Gy (W) in the
clinical trials for glioblastoma multiforme patients at the Finnish BNCT facility reported
by Joensuu et al. (2003). In BNCT of locally recurred head and neck cancer reported by
Kankaanranta et al. (2007), the median average tumor dose delivered to the gross tumor
volume during the first scheduled BNCT was 21 Gy (W) (range, 14–29 Gy [W]) and
during the second BNCT 20 Gy (W) (range, 15–24 Gy [W]). An average of 91% of these
tumor doses resulted from the boron neutron capture reactions.
 According to ICRU (International Commission of Radiation Units and Measurements)
guidelines, the patient dose uncertainty in external radiotherapy should not exceed 5%
(ICRU 26). In BNCT, the uncertainty of the computed absorbed dose has been estimated
to be 20% (1 SD, standard deviation) in the normal brain (Seppälä 2002). The uncertainty
evaluated in estimating the boron concentration in normal tissue is 30% (Kortesniemi
2002), which is the most important source of inaccuracies in BNCT dose computation.
With no boron dose uncertainty, the uncertainty of the computed absorbed total dose
would be 8% (1 SD) (Seppälä 2002). It should be also taken into account that the 30%
uncertainty (Kortesniemi 2002) in the boron concentration in normal tissue is estimated
using the average dispersion of the boron concentration determined in brain tissue samples
by a limited number of patients (Coderre et al. 1998, Elowitz et al. 1998). The true
uncertainty of the boron concentration in the brain is unknown, and the uncertainty of the
boron dose in the normal brain could therefore be even higher than the 30% reported. The
majority of European research groups involved in the development of BNCT have
prepared the report “Recommendations for the Dosimetry of Boron Neutron Capture
Therapy (BNCT)” published by the Nuclear Research & Consultancy Group (NRG). The
report covers the guidelines for the basic characterisation and dosimetry of the epithermal
(and thermal) neutron beams used in BNCT (Voorbraak and Järvinen 2003). However,
this report includes no guidelines determining boron concentrations or calculations due to
the boron neutron capture reaction.
At the moment, the drifting of boron from blood to tumour and the spatial and
temporal accumulation of boron in the brain are not exactly known. In Finnish clinical
BNCT practice, the whole blood boron concentration is routinely determined during and
after BPA-F infusion from periodic blood samples using inductively coupled plasma-
atomic emission spectrometry (ICP-AES) (Coderre and Morris 1999, Laakso et al. 2001,
Kortesniemi 2002, Kortesniemi et al. 2004, Linko et al. 2008). The whole blood boron
concentration during irradiation is calculated from previously determined blood boron
concentrations using kinetic models (Kortesniemi 2002, Ryynänen 2002). The boron
concentration in the tumour and brain tissue during the irradiation are estimated using
simple blood-to-brain and blood-to-tumour ratio values: 1:1 for blood-to-brain, and 1:3.5
for blood-to-tumour (Coderre et al. 1998). In the Finnish BNCT of brain tumours, neutron
irradiation was started approximately 45 min after the completion of infusion (Joensuu et
al. 2003). The blood-to-brain and blood-to-tumour ratios used in Finland and in common
BNCT clinical practice are based on a study by Coderre et al. (1998). Coderre et al.
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(1998) and Elowitz et al. (1998) measured boron concentration invasively in surgical
samples after BPA-F infusion. In patients with suspected or confirmed glioblastoma
multiforme, the results of the histological findings indicated 1.4 (Elowitz et al. 1998) to 4
(Coderre et al. 1998) mean blood-to-tumour boron concentration ratios as well as high
variation in the blood-to-tumour ratio inside particular tumours (Elowitz et al. 1998). New
non-invasive methods are therefore needed to determine or monitor boron concentrations
in the brain.
Several studies have examined, the suitability of positron emission tomography (PET)
for treatment planning purposes (Aihara et al. 2006, Imahori et al. 1998a, 1998b, 1998c,
Nichols et al. 2002). In PET, the 18F-labelled BPA is detected in the brain. In Finland, 18F
BPA PET studies have been used to study the suitability of patients, i.e. the accumulation
of boron carrier for BNCT (Kankaanranta et al. 2007). Prompt gamma spectroscopy
(PGS) has also been investigated for boron determination (Verbakel 2001, Verbakel et al.
2003, Munck af Rosenschöld et al. 2001, Wittig et al. 2008). In addition, Bergenheim et
al. (2005) have used microdialysis to study BPA distribution in glioblastoma patients
during BNCT treatment. Several magnetic resonance techniques have been proposed for
boron carrier detection. 11B or 10B magnetic resonance imaging (MRI) and MR
spectroscopic methods have been reported for boron detection (Bendel et al. 1994, Bendel
and Sauerwein 2001, Campanella et al. 2002, Kabalka et al. 1997). Recently, 19F magnetic
resonance spectroscopy (MRS) has also been used to detect 19F-labelled BPA (Porcari et
al. 2008, 2009). Zuo et al. (1999) have proposed the possibility to apply clinically widely
used proton MR spectroscopy (1H MRS) for selective BPA-F detection and they detected
aromatic signals of BPA in vivo at 1.5 T. Later, Bendel et al. (2005a, 2005b) studied the
MRS imaging (MRSI) of BPA-F with animals at high magnetic field.
 1.2. Magnetic resonance spectroscopy
Nuclear magnetic resonance (NMR) spectroscopy (abbreviated as MRS in clinical
sciences) is a non-invasive tool to study tissue metabolism in vivo in a clinical
environment. Nowadays, MRS is used to investigate several diseases. The most common
application of 1H MRS in medicine is the investigation of neurological diseases
(Danielsen and Ross 1999, Lin et al. 2005) such as brain tumours, epilepsy, stroke and
neonatal hypoxia. 1H MRS can also applied in other body areas such as liver (Fischbach
and Bruhn 2008), muscle (Boesch et al. 2006) and heart (Horn 2006). Phosphorus MRS
(31P MRS) can study energy metabolism and has been used clinically in several
applications as on the heart (Horn 2006), liver (Solga et al. 2005) and muscle (Mattei et al.
2004). In addition, other nuclei - primarily carbon (13C), fluorine (19F) and sodium (23Na) -
have been used in MRS, but mainly for research purposes (Babsky et al. 2008, Klomp et
al. 2007, Kurhanewicz et al. 2008, Procissi et al. 2007).
The brain metabolites N-acetylaspartate (NAA), total creatine (creatine +
phoshpocreatine; tCr), total choline (resonance composed mainly of choline-containing
phospholipids; Cho) and lactate (Lac) are commonly monitored in in vivo 1H MRS during
the investigation of neurological diseases. NAA is a neuronal amino acid that typically
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decreases in tumours and degenerative and inflammatory brain diseases (Danielsen and
Ross 1999, Ross and Bluml 2001). Choline-containing phospholipids in membranes are
released during active myelin breakdown or rapid cell proliferation (Danielsen and Ross
1999). Therefore, increased Cho signal is detected in certain tumours during active
processes. Total creatine (tCr) is the sum of the creatine (Cr) and phosphocreatine (PCr)
signals  and  is  related  to  brain  energy  metabolism  (Danielsen  and  Ross  1999,  Ross  and
Bluml  2001).  The  intensity  of  the  tCr  signal  remains  relatively  constant  and  resistant  to
changes, but major changes appear in destructive pathology, such as malignant tumours
(Danielsen and Ross 1999). Lactate, a marker of anaerobic metabolism, is an end-product
of oxidative metabolism (Danielsen and Ross 1999). Elevated lactate signals can be
detected after hypoxia (as in stroke), but also in many neurological diseases such as
tumours, Canavan disease, and intracerebral hemorrhage (Danielsen and Ross 1999).
Several other metabolites, such as myo-inositol (mI), scyllo-Inositol (sI), Glucose (Glc),
Glutamate (Glu), and Glutamine (Gln), can also be detected in the brain 1H MR spectrum
(Ross and Bluml 2001).
The transverse relaxations times (T2) of different brain metabolite protons vary (Frahm
et al. 1989, Mlynárik et al. 2001). In a typical clinical MRS study, the echo time (TE) is
chosen according to the metabolites of interest. TE values of 20 to 40, 144 or 288 ms are
typical in the clinical setting. In the so-called “short TE spectra”, a TE value of 20 to 40
ms is used, and several metabolites can be detected in the spectrum (Figure 1). In the
“long TE spectra”, fewer signals can be detected (NAA, Cho, Cr, lac), and the spectrum
baseline is flat, as macromolecule and lipid signals have essentially decayed to noise level.
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Figure 1 A 3.0 T single voxel 1H MR spectrum of brain white matter (TE=37 ms and TR=2000
ms) of a healthy adult. N-acetylaspartate (NAA), total creatine (tCr), total choline (Cho), myo-
inositol (mI), glutamate plus glutamine (Glx), lactate (Lac), lipid (Lip) and macromolecule (MM)
signals appear  in the spectrum.
 The protons of NMR-visible brain metabolites resonate mainly at a chemical shift
range of 1 to 4 ppm (parts per million). This is the spectral region normally used for
clinical studies. The protons of water molecules cause a major resonance at 4.7 ppm. The
water  signal  is  usually  suppressed  during  the  MRS  sequence  to  avoid  any  overlap  with
low-intensity metabolite signals and a distorted baseline, as the water concentration in the
brain is approximately 10 000–fold higher than the concentration of brain metabolites. In
adult white matter, the concentrations are approximately 6-9 mM for NAA, 1-2 mM for
Cho, and 5.2-5.7 mM for Cr (Frahm et al. 1989, Pan et al. 1998, Pouwels and Frahm
1998, Tan et al. 1998, Wang and Li 1998, Hetherington et al. 1994, Graaf et al. 2007).
Aromatic protons resonate at 7 to 9 ppm. Only a few brain metabolite signals appear in
“the aromatic region” of the 1H MRS spectrum (Aru`s et al. 1985, Gadian et al. 1986,
Kreis et al. 1995, Mori et al. 1998, Rothman et al. 1997, Shungu and Glickson 1993).
15
Exchangeable NAA amide protons resonate at ~7.9 ppm, the exchangeable amino protons
of Glu and protein at 6.8 ppm, and Cr at 6.71 ppm. In addition, ATP and nucleosides
resonate at 8.45 ppm and 8.22 ppm, homocarnosine at 8.00 and 7.04 ppm, and tryptophan
at 7.29 ppm. However, the intensities of these signals are usually too low to be detected
with typical measurement settings (voxel size and measurement duration). Therefore, this
spectral range is normally “clean of 1H signals” and is not used in clinical practice. Zuo et
al. (1999) reported that aromatic signals of BPA at 7.0 to 7.5 ppm can be detected in vivo
using 1H MRS. In theory, this offers much needed possibilities to study the spatial and
temporal distribution and concentration of BPA in the brain non-invasively. The aromatic
proton signals of BPA would be ideal for BPA detection because normal brain metabolite
signals do not overlap with them. Bendel et al. (2005b) have optimised MRS and MRSI
sequences for BPA detection, but have performed no studies on humans. Bendel et al.
(2001) have studied 1H  MRS  detection  of  another  clinically  used 10B-carrier, BSH. The
problem with 1H  MRS  detection  is,  however,  that  the  broad  signal  of  BSH  protons
coincides almost precisely with those of lipid molecules.
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2. AIMS OF THE STUDY
The goal of this thesis was to
1. study BPA quantification with phantoms at 1.5 and 3.0 T using single voxel 1H MRS,
and at 1.5 T using acquisition-weighted 1H MRSI (Papers I, IV and V).
2. determine the detection limit of BPA in phantom conditions at 1.5 T and 3.0 T using
single voxel 1H  MRS  and  two  different  voxel  sizes,  and  at  1.5  T  using  acquisition-
weighted 1H MRSI (Papers II and V).
3. evaluate the validity of 1H MRS as a clinical tool for BNCT treatment planning (Paper
III and the thesis).
4. evaluate the clinical feasibility of 1H MRS-based BPA detection in BNCT.
This thesis presents the results of in vivo BPA-F 1H MRS measurements, including
previously unpublished data.
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3. MAGNETIC RESONANCE SPECTROSCOPY OF
BORONOPHENYLALANINE FRUCTOSE
3.1 Localisation schemes of MRS
In MRS, the localisation of voxel is based on B0 magnetic field gradients and frequency
selective RF pulses. Point Resolved Spectroscopy (PRESS) (Bottomley 1987) and
Stimulated Echo Acquisition Mode (STEAM) (Frahm et al. 1987) are commonly used
localisation methods in clinical 1H MRS. PRESS uses one 90° and two 180° slice selective
RF pulses (Figure 2), whereas STEAM is based on three 90° slice selective RF pulses. Use
of the basic Spin Echo (SE) localisation method containing a 90° followed by one 180° RF
pulse is also possible. However, in SE method, volume selection is possible only in two
dimensions as a slice or a bar. Image Selected in vivo Spectroscopy (ISIS) is typically used
in 31P MRS studies (Ordidge et al. 1986). Localisation by Adiabatic Selective Refocusing
(LASER) is a localisation scheme that utilizes adiabatic excitation and refocusing RF
pulses (Garwood and DelaBarre 2001, Kinchesh and Ordidge 2005). The advantages of
LASER  include  improved  tolerance  to  chemical  shift  artefacts  and  the  effects  of  J-
coupling in a coupled spin system. In neurological 1H MRS studies, frequency selective
excitation methods such as CHemical Shift Selective (CHESS) imaging (Haase et al.
1985) are typically used for water suppression. Other water suppression techniques,
include Water Eliminated Fourier Transform (WEFT) (Gupta 1976) or Driven Equilibrium
Fourier Transform method, which utilise differences in relaxation parameters (DEFT)
(Becker et al. 1969).
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Figure 2 Schematic representation of the PRESS sequence.The timing of the 90° and  180°
slice selective RF pulses (RF) and the three orthogonal gradients (Gx, Gy, Gz) are shown.  Two
pairs of crusher gradients surrounding 180° slice selective refocusing pulses ensure the selection
of the desired coherences, while simultaneously destroying all others.
Analoguously to MRI, in MRSI, phase encoding is used to collect spectral data
covering two- or tree-dimensional volume (i.e. one large volume is "divided" into several
smaller voxels, each containing an MRS spectrum) (Brown et al. 1982, Maudsley et al.
1983). MRSI is technically more challenging than single voxel MRS; the volume
definition is less optimal, susceptibility to lipid contamination is higher, shimming the
volume of interest (VOI) can be difficult and the measurement duration can be relatively
long. In brain studies, an outer volume saturation and careful localisation of the VOI are
typically used for lipid suppression. In the body area, where the VOI can contain lipids,
lipid magnetization can be destroyed using chemical shift selective pulses (as in CHESS
water suppression) or inversion-recovery (IR) methods.
The nominal voxel size of MRSI is defined by the field of view (FOV) divided by the
number of phase encoding steps. In MRSI, however, due to few phase encoding sampling
points, the point spread function (PSF) considerably influences the actual spatial
resolution (Vikhoff-Baaz et al. 2001). To decrease the truncation artefact (Gibb’s ringing
artefact) in spatial dimensions, the apodization function is usually applied before Fourier
transformation in the spatial dimensions. This, however, will widen the main peak and
increase the actual voxel size. Because the duration of a conventional MRSI acquisition is
relatively long, several fast MRSI methods have been developed. Conventional methods,
such as circular or elliptical k-space sampling (Maudsley et al. 1994, Hugg et al. 1996),
are usually available in clinical MR imagers. Some manufacturers also offer “weighted”
acquisition methods (Pohmann and von Kienlin 2001) where k-space apodization is
applied already during the acquisition, thus requiring more than one average. In Proton
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Echo Planar Spectroscopic Imaging (PEPSI) (Mansfield 1984, Guilfoyle and Mansfield
1985, Guilfoyle et al. 1989, Posse et al. 1994), various echoes are detected after a 180° RF
pulse. As with turbo spin echo MRI, turbo spectroscopic imaging (TSI) uses extra 180°
refocusing pulses to detect multiple echoes (Duyn and Moonen 1993). Nowadays, parallel
imaging methods (Sodickson and Manning 1997, Pruessmann et al. 1999, Griswold et al.
2002) are also available for clinical MRSI (Dydak et al. 2001, Dydak et al. 2003).
Techniques such as Spectral Localisation by IMaging (SLIM) (Hu et al. 1988) or Spectral
Localisation with Optimal pOint Spread function (SLOOP) (Von Kielin and Mejia 1991)
apply prior knowledge of the anatomy of the object to be measured in order to reduce the
measurement duration. It should be noted that in several fast MRSI methods, the
shortening of measurement duration is achieved, at least, to some degree in cost of spatial
resolution, signal-to-noise and/or spectral resolution.
3.2 Quantification of metabolites in MRS
In  principle,  MRS  allows,  determination  of  the  absolute  concentration  of  the  metabolite
signal measured. However, various difficulties are involved in using MRS to reliably
determine the absolute concentration (Graaf 2007). In quantification, a calibration
compound with  a  known concentration  must  serve  as  a  reference.  Quantification  can  be
carried out using either an external or an internal concentration reference. An internal
water signal commonly serves as the internal concentration reference. However, the water
content of the tissue varies in pathology and between different tissue types (Graaf 2007).
The external concentration references are based on separate phantom measurements, such
as those in the LCModel programme (Provencher 1993). The downside of the external
reference method is its sensitivity to various technical variables. In quantification,
corrections are necessary due to differences in the T1 and  T2 relaxation times of the
reference and metabolite compounds (when TR is too short compared to the longest T1
and/or when long TE-values are used), diffusion, susceptibility, and also coil loading if a
phantom replacement method is used. Relative concentrations (i.e. the intensity ratio
between the NAA signals and the Cho signal) are commonly used in clinical practice (Lin
et al. 2005). The corrected intensity of metabolite signal Sm can be determined by (Graaf
2007)
(2) Sm=SmmCT1,mCT2,mCnOe,mCADC,mCJ,mCloc,mCrf,m
where Smm is the intensity of the metabolite signal measured, and CT1,m CT2,m CnOe,m
CADC,m CJ,m Cloc,m and Crf,m are the correction factors of signals measured for partial
saturation due to incomplete T1 relaxation, T2 relaxation, nuclear Overhauser effects,
diffusion, amplitude and phase modulation due to J-coupling, deviations from the ideal
localisation profile, amplitude and phase distortions due to specific RF pulse combinations
such as binominal RF pulse, respectively. The corrected intensity of reference signal Sref
can be expressed by (Graaf 2007)
20
(3) Sref=SrmCT1,rCT2,rCnOe,rCADCrCJ,rCloc,rCrf,r
where Srm is the intensity of the reference signal measured, and CT1,r CT2,r CnOe,r CADCr
CJ,r Cloc,r and Crf,r  are correction factors for the reference signal, as described in Eq. (2).
The absolute concentration [m] can be determined using equation (Graaf, 2007)
(4) [ ] gainavn
ref
m CCCref
S
Sm ][×÷
÷
ø
ö
ç
ç
è
æ
=
where Sm is the intensity of the corrected metabolite signal, Sfer is the intensity of the
corrected reference signal, [ref] is the concentration of the reference compound, Cn is the
correction for the number of equivalent nuclei for each resonance, Cav is the correction for
the number of averages and Cgain is the correction for the receiver gain settings.
In an uncoupled spin system, if the PRESS sequence is used, the MRS signal intensity
I can be expressed as
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where I0 corresponds to the MRS signal intensity of the theoretical situation where
TE=0.
For the STEAM sequence, the MRS signal intensity I can be expressed as
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where TM is the mixing time. The relaxation times T1 and T2 can be solved using Eq.
(5) from the data recorded with various TE and TR values.
3.3 1H MRS of boronophenylalanine fructose
Boronophenylalanine is an amino acid, a modified phenylalanine with a boronic acid
group, -B(OH)2, in para-position to the phenyl ring. Due to the limited water solubility of
pure BPA at physiological pH, BPA infusion is administrated as a fructose complex (Mori
et al. 1989, Yoshino et al. 1989). The likely structure of a BPA-fructose complex (BPA-F,
molecular weigth 351.3 g/mol) appears in Figure 3 (Shull et al. 2000). As an amino acid
analogue, BPA can accumulate actively into tumour cells (Nakagawa et al. 2007). BPA is
21
considired to distribute uniformly in both the nucleus and the cytoplasm (Coderre et al.
1998). In addition, partial disruption of the blood-brain barrier (BBB) within the tumour
likely increases boron accumulation in tumour (Yang et al. 1997). The four aromatic
protons of BPA form a strongly coupled spin system. At 1.5 T, the aromatic proton spin
system consists of two pairs of chemically equivalent protons, AA’BB’. At 3.0 T, the spin
system can be notated as AA’XX’ because the difference between resonance frequencies
is significantly higher than the coupling constant.
The coupled spin system causes difficulties in MRS when typical clinical MRS
sequences are used (i.e. with non-zero TE). The phases and amplitudes of the signal are
modulated  with  changing  TE.  Therefore,  the  T2 determination is not so straightforward,
and the signal intensity follows no simple exponential decay as a function of TE according
Eqs. (5) or (6).
O
O
NH3
B
O
O
O
O
OH
HO
Figure 3 The likely structure of a BPA-fructose complex in water at physiological pH (Shull et
al. 2000).
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4. MATERIALS AND METHODS
4.1 Phantom studies
4.1.1. Phantoms
The phantoms contained aqueous BPA-F solutions with various BPA concentrations
(details in Papers I, II, III, IV and V) and tissue modelling firm 2% agarose gel (Indubiose
A37,  BioSepra)  with  a  BPA concentration  of  7.2  mM (Paper  I).  To  study  the  effects  of
blood on 1H MRS quality, BPA-F phantoms containing whole blood and blood plasma,
both  with  BPA  concentration  of  4.6  mM,  were  prepared  (Paper  III).  In  addition,  whole
blood phantom with 100 mg of absorbable hemostat (Surgicel Fibrillar, oxidised
regenerated cellulose, Ethicon, Inc.) and blood plasma phantom were used. In order to
increase the coil loading to the level typically encountered in human MRS studies, a flask
containing BPA-F solution (or agarose gel with BPA-F) was placed in a spherical 4500 ml
plastic phantom filled with 0.1 mM MnCl2-solution doped with NaCl (0.4%).
4.2.1. MR hardware and pulse sequences
The MRS and MRSI were performed with clinical 1.5 T and 3.0 T MR imagers (GE Signa
Horizon LX EchoSpeed, GE Medical Systems, Fremont, GA, USA) (Papers I and II) and
a 1.5 T MR imager (Siemens Magnetom Sonata, Siemens Medical Systems, Erlangen,
Germany) (Papers III, IV and V). PRESS (Papers I, II, III, IV and V) and STEAM (Paper
II) localisation sequences were used with the CHESS water suppression scheme.
 4.2.2. Simulation studies
A Virtual NMR Spectrometer simulation program (Nicholas et al. 2000) was used to
calculate the response curves of the BPA aromatic proton spin system to the PRESS
(Paper I) and STEAM (Paper II) sequences at 1.5 and 3.0 T. The response curves
calculated with various TE values (details in Papers I and II) served in T2 determination
using Eq.
(7) 20)(
T
TE
TEevolJTE eMMM
-
-=
where MJ-evol(TE) is  the calculated intensity at  a given TE. This term can also serve to
correct for J-evolution effects when an uncoupled resonance serves as a concentration
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reference. In this case, the intensity correction factor due to J-evolution dTE can be
calculated using Eq.
(8)
)(
)0(
TEevoJ
evolJ
TE M
M
d
-
-=
 where MJ-evol(0) is the intensity calculated at TE of 0 ms and MJ-evol(TE) is the intensity
calculated for the TE used in the measurement.
4.2.3. Relaxation times
The relaxation times T1 and  T2 were determined for BPA-F in aqueous solution and
agarose gel at 1.5 and 3.0 T (Papers I and II). In T1 determination, the MRS measurements
were carried out with various TR values while keeping TE constant and Eq. (5) (and Eq.
(6) for the STEAM sequence in Paper II) was fitted to the signal intensities measured. T2
was determined by fitting Eq. (7) to the intensities measured with various TE. In addition,
the T1 and T2 relaxation times of water in aqueous BPA-F phantom were determined using
Eqs. (5) and (6), respectively.
4.2.4. Quantification
BPA quantification was studied with BPA-F agarose gel and aqueous BPA-F phantoms
using single voxel MRS at 1.5 T and 3.0 T (Papers I and II). The quantification was
carried out using Eq. (4) with external and internal concentration references. Intensity
corrections for T1 and  T2 relaxation and J-evolution were applied. For comparison,
quantification was also done without intensity corrections.
In addition, BPA quantification was studied using MRSI at 1.5 T (Papers IV and V). In
the MRSI study, Cr was added to aqueous BPA-F phantom as an internal concentration
reference. For comparison, quantification was also done using single voxel MRS and the
same measurement duration used in the MRSI study (Papers IV and V). Intensity
corrections for T1 effects were performed, but not for T2 due to the relatively short TE.
4.2.5. Detection limits
The detection limit of BPA was evaluated in phantom conditions with a single voxel MRS
(Paper II) and acquisition-weighted MRSI (Paper V). Single voxel MRS studies were
carried out at 1.5 T and 3.0 T using two different voxel volumes (15 mm3 and 20 mm3)
and a clinically acceptable measurement duration (approximately 10 min, including
automatic shimming and water suppression adjustments). The BPA detection limit, using
acquisition-weighted MRSI, was determined at 1.5 T using a ~17 min MRSI protocol with
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a nominal spatial resolution of 10 (RL) x 10 (AP) x 7.5 (SI) mm3 (one-fold spatial zero
filling in the SI direction prior to Fourier transformation) (Paper V). An acquisition-
weighted/elliptical scanning method with post-acquisition k-space filtering was used to
reduce the measurement time significantly without losses in SNR.
4.2.6. Effects of blood on 1H MRS quality
Glioma patients usually undergo brain surgery prior to BNCT. Consequently, the gross
tumour volume (GTV) often includes a resection cavity containing heamostatic agents and
coagulated blood that have detrimental effects on the MR spectrum quality. The blood-
originated interference in the 1H MRS was studied with phantoms containing whole blood
and blood plasma with BPA-F, whole blood with absorbable haemostat, and blood plasma
(Paper III).
4.2 In vivo studies
4.2.1 Patients
From December 2003 to February 2008, 1H  MRS/MRSI  was  performed  on  the  day  of
BNCT for ten patients. Table 1 shows the patient age, sex and BNCT protocol. In BNCT
protocol P01, the patients exhibited newly diagnosed glioblastoma multiforme (GBM). In
protocol P01, BNCT was given as the first postoperative radiation treatment. No other
concomitant or adjuvant treatments were offered. In the BNCT protocol P03, patients
showed recurrent or progressing GBM or anaplastic astrocytoma gradus III, and had
undergone prior cranial conventional external beam radiotherapy. Patients 2 and 3, who
were treated under the BNCT protocol HN, had inoperable, recurrent, histologically
confirmed head and neck cancer. Detailed criteria for protocols P01 and P03 appear in a
paper by Joensuu et al. (2003), and for protocol HN in a paper by Kankaanranta et al.
(2007).
All patients provided their written informed consent prior to the MRS. The study was
approved by an institutional Ethics Committee (HUS40/E6/02) and the National Agency
for Medicines, Finland.
4.2.2. MRS/MRSI EXPERIMENTAL SETUP
1H MRS and 3D 1H  MRSI  measurements  were  performed  for  nine  patients  with  1.5  T
(Siemens Magnetom Sonata or Siemens Avanto, Erlangen, Germany), and 1H MRS for
one  patient  with  3.0  T  (Philips  Intera  Achieva,  Best,  Netherlands)  MRI  scanners.  A
standard receiver birdcage head coil was used with a Siemens Magnetom Sonata, and a
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transmit/receive head coil with a Philips Intera imager. Both transmit/receive (patient 9)
and standard receive (patient 10) head coils were used with Siemens Avanto imager.
PRESS localisation with a CHESS water suppression scheme was used. Spectral post-
processing and lineshape fitting for patients 9 and 10 were carried out using the standard
software package of the MRI scanner (Siemens Syngo MMWP, VE23A).
3D MRSI studies were performed for patients 5 to 10 (Table 1) with 1.5 T MRI
imagers using a TE of 30 ms and TR of 1500 ms. The number of averages was two, and
the number of phase encoding steps was 16 x 16 x 8. Weighted/elliptical sampling with a
50% Hamming k-space post-acquisition filter was used. The VOI size was adjusted to
cover the tumour and normal brain as much as possible, but also to avoid intracranial
lipids and air cavities in of skull base. The total measurement duration of 3D MRSI was
17 min. FOV and nominal voxel sizes appear in Table 1.
A single voxel MRS study was performed for patients 1 to 9. TE was 30 ms at 1.5 T
and 35 ms at 3.0 T measurements. TR was 1600 ms, except for patients 1 and 2, for whom
a TR of 1500 ms was used. The nominal voxel size and number of averages appear in the
Table 1.
MRS/MRSI studies were performed patients 1 to 9 after BNCT. In contrast, patients 3
and 9 underwent single voxel MRS before BNCT alongside with treatment planning MRI.
Patient  9  underwent  a  3D MRSI  one  month  after  treatment  with  a  one-month  follow-up
MRI. Patient 10 underwent a 3D MRSI during the infusion, begining 11 min before the
end of the infusion and ending 6 min after the completion of the infusion. In contrast, 3D
MRSI data were also collected alongside with treatment planning MRI four days before
the infusion. The mean whole blood boron concentrations during the 1H MRSI/MRS
(Table 5) were determined from the bi-exponential kinetic models based on the pre- and
post-MRSI whole blood samples analysed (Kortesniemi et al. 2004). The blood boron
concentration curves of patients 9 and 10, calculated using whole blood boron
concentrations measured by the ICP-AES (Laakso et al. 2001), appear in Figures 4 and 5.
The timing of the irradiations and MRSI are indicated with dotted vertical lines.
Figure 4 The (ICP-AES) whole blood boron concentration (circles) measured from patient 9
with estimated values (curve). The timing of irradiation is indicated with solid vertical lines and
the timing of MRSI with dotted vertical lines.
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Figure 5  The (ICP-AES) whole blood boron concentration (circles) measured from patient 10
with estimated values (curve). The timing of irradiation is indicated with solid vertical lines and
the timing of MRSI with dotted vertical lines.
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Table 1. BNCT protocol and details of the MRS measurements of patients 1-10. In the BNCT protocol P01, the patients exhibited newly diagnosed
glioblastoma multiforme (GBM), and BNCT was given as the first postoperative radiation treatment. In the BNCT protocol P03, patients showed
recurrent or progressing GBM or anaplastic strocytoma gradus III, and had undergone prior cranial conventional external beam radiotherapy. In the
BNCT protocol HN, patients had inoperable, recurrent, histologically confirmed head and neck cancer.
Single Voxel MRS MRSI
Pt. Age Sex BNCT
prot.
Field strength and
MR imager
Vox. size  cm3
(AP)x(RL)x(SI)
NSA Nominal vox. size cm3
(AP)x(RL)x(SI)
FOV cm3
(AP)x(RL)x(SI)
1 65 F P01 1.5 T Sonata 1.8x1.8x1.8 304 - -
2 44 M HN 1.5 T Sonata 2.0x2.0x2.0 256 - -
3 61 M HN 1.5 T Sonata 1.8x1.8x1.8 304 - -
4 42 F P03 3.0 T Achieva 2.0x2.0x2.0 176 - -
5 35 M P03 1.5 T Sonata 1.7x1.5x1.5 304 1.0x1.0x0.75* 16x16x12
6 54 M P01 1.5 T Sonata 2.0x2.0x1.5 304 1.5x1.5x1.5 24x24x12
7 52 M P03 1.5 T Sonata 2.5x2.5x2.5 256 1.0x1.0x0.75* 16x16x12
8 65 M P01 1.5 T Sonata 1.8x2.4x1.7 304 1.0x1.0x0.75* 16x16x12
9 22 M P03 1.5T Avanto 2.0x1.8x2.0 128 1.1x1.1x0.75* 18x18x12
10 48 M P03 1.5T Avanto - - 1.1x1.1x0.75* 18x18x12
*one-fold spatial zero-filling in the SI direction
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5. RESULTS
5.1 Phantom studies: relaxation times, detection limits and
quantification of BPA
The aromatic proton relaxation times of BPA in aqueous solution and 2% agarose gel
phantom with a BPA concentration of 7.2 mM measured with PRESS sequence are shown
in Table 2. The corresponding values for water appear in Papers I and II. The T2
determination of BPA in aqueous solution and water was carried out in both studies
presented in Papers I and II. The values shown in Table 2 are based on the study presented
in Paper I. The detection limits obtained for BPA at 1.5 and 3.0 T (Papers II and V) are
shown in Table 3.
Table 2.  The relaxation times of aromatic protons of BPA at 1.5 and 3.0 T.
BPA aqueous solution BPA agarose gel phantom
T1(ms) T2(ms) T1(ms) T2(ms)
1.5 T 935 335 975 180
3.0 T 785 225 870 175
Table 3. The detection limits for BPA at 1.5 and 3.0 T.
Detection limit (mM)
Study Nominal voxel size
(mm3)
1.5T 3.0T
Single voxel MRS 15x15x15 2.2 1.4
Single voxel MRS 20x20x20 1.4 0.7
3D MSRI 10x10x7.5* 1.0 -
*one-fold zero-filling in the SI direction
The BPA quantification results for aqueous BPA-F solutions and BPA-F agarose gel
phantom (Papers I, II, IV and V) appear in Table 4, which shows the quantification results
based on an internal concentration reference. The results based on an external
concentration reference appear in Paper I. The results of quantification based on the
STEAM sequence and corresponding quantification results without intensity corrections
(relaxation and J-evolution effects) appear in Paper II.
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Table 4. BPA quantification results for BPA aqueous solutions and BPA agarose gel
phantom using the PRESS sequence and an internal concentration reference.
True
cBPA
(mM)
Measured cBPA
(mM)
MRS/MRSI Nominal
voxel size
(mm3)
Phantom Concentration
reference
1.5 T 3.0 T
MRSI 10x10x7.5* BPA-F/Cr
solution
Cr 3.0 2.89 -
Single
Voxel MRS
15×15×15 BPA-F/Cr
solution
Cr 3.0 3.01  -
Single
Voxel MRS
18×18×18 BPA-F/Cr
solution
Cr 3.0 3.00 -
Single
Voxel MRS
22×22×22 BPA-F/Cr
solution
Cr 3.0 2.81 -
Single
Voxel MRS
20x20x20 aq BPA-F
solution
internal water 5.8 6.3 5.9
Single
Voxel MRS
15x15x15 2% agarose gel
with BPA-F
internal water 7.2 8.5 7.7
Single
Voxel MRS
15x15x15 aq BPA-F
solution
internal water 11.5 13.5 13.4
Single
Voxel MRS
20x20x20 aq BPA-F
solution
internal water 23.1 - 23.2
*one-fold zero-filling in SI direction
Spectra measured from whole blood with 100 mg of absorbable hemostat, blood
plasma, whole blood and blood plasma doped with BPA-F (BPA concentration 4.6 mM)
are presented in Figure 6. The blood-originated interference in the 1H MRS spectrum of
BPA is evident in spectrum D, which indicates that the presence of blood can obscure a
relatively high BPA concentration. The small additional peaks located at 7.5–7.9 ppm in
the BPA aqueous solution spectra have increased intensities in the spectrum recorded from
the blood plasma/BPA-F phantom (spectrum B), thus indicating possible changes in the
stability of the BPA-F complex in the plasma environment.
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Figure 6 1.5 T 1H MR phantom spectra (Paper III). The spectrum from BPA-F aqueous
phantom (A) with a BPA concentration of 23.1mM is approximately  scaled to correspond to the
same BPA concentration (4.6 mM) as in blood plasma/BPA-F (spectrum B) and whole blood/BPA-
F (spectrum D) phantoms. Spectra from blood plasma appear in (C) and whole blood in (E).
5.2 Patient study: blood boron concentrations and in vivo BPA
detection in the brain
The whole blood boron concentrations during the MRS measurements for patients 1 to 10
appear in Table 5. The “Results of MRS” column indicates whether (+ or -) the signals
(SNR>1) of the spectrum aromatic area were detected. The confirmation of aromatic
signals detection was done by visual inspection of the spectra (two independent viewers
MT, SH). The criterion for a positive detection was the identification of the peak or peak
pattern in the aromatic region (SNR>1).  The results of the MRS/MRSI studies of patients
1 and 2 have been published in Paper III.
31
Table 5. The estimated whole blood boron concentrations of patients 1 to 10 during MRS. The “BNCT protocol” column indicates the BNCT
treatment protocol of the patient: P01( newly diagnosed GBM, and BNCT was given as the first postoperative radiation treatment), P03 (recurrent or
progressing GBM or anaplastic strocytoma gradus III, and had undergone prior cranial conventional external beam radiotherapy) or HN ( inoperable,
recurrent, histologically confirmed head and neck cancer). The “Results of MRS”column  indicates whether (+ or -) the signals (SNR>1) in aromatic
region were detected in tumour on the day of BNCT. In the contralateral brain tissue, there where no detectable signals in the aromatic spectral region.
Pt. Age Sex BNCT
protocol
BPA-F infusion
(mg BPA/kg)
Whole blood boron
concentration (mg/kg)
during MRS
MRS timing (min)
after the completion
of BPA-F infusion
MRS timing
(min) after the
completion of
irradiation II
Results of
MRS
1 65 F P01 450 12 265 140 +
2 44 M HN 400 14 170 125 -
3 61 M HN 400 16 219 90 -
4 42 F P03 450 16 203 69 -
5 35 M P03 290 12 192 70 -
6 54 M P01 500 19 204 89 -
7 52 M P03 290 9 215 80 -
8 65 M P01 500 25 216 80 -
9 22 M P03 450 14 250 89 +
10 48 M P03 450 38 ** ** +
** MRSI study began 11 min before the completion of the infusion and ended 6 min after the end of the infusion
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The tumour and contralateral brain tissue 3D MR spectra of patient 9 on the day of
BNCT (89 min after completion of the irradiation) (A and B) and one month after BNCT
(E and F) appear in Figure 7. The spectra measured on the day of BNCT indicates that two
signals can be detected in the tumour spectrum. The spectra measured on the day of BNCT
appear also without baseline correction (Figure 7 C and D). Figure 8 shows the tumour
and contralateral  brain  tissue  MRSI  spectra  of  patient  10  before  and  during/after  BPA-F
infusion (the MRSI of patient 10 began 11 min before completion of the infusion and
ended 6 min after completion of the infusion). For comparison, the spectrum of 3.0 mM
BPA aqueous solution (with 10.1 mM creatine) appears in Figures 7 and 8. Figures 9 and
10 show the metabolite maps based on the lineshape-fitting of the data from the aromatic
region  area  after  BNCT  (patient  9)  or  during/after  BPA-F  infusion  (patient  10).  The
metabolite maps indicate that aromatic signals were detected in several voxels in the
tumour volumes of patients 9 and 10, whereas no signals were detected in the aromatic
region of the spectra recorded from normal brain tissue. Figure 11 presents “the metabolite
region” (0.5 - 4.2 ppm) of spectra A and B presented in Figures 7 (above) and 8 (below),
demonstrating  the  quality  of  the  spectrum.  The  Full  Width  at  Half  Maximum  (FWHM)
Cho signal in the tumour spectrum was 3.9 Hz for patient 9 (Figure 11, spectrum at right,
above) and 6.2 Hz for patient 10 (Figure 11, spectrum at right, below), respectively. In
Figure 12, the spectrum from aqueous BPA-F/Cr solution (A) and the tumour spectra of
patients  9  (B)  and  10  (C)  are  shown  again.  The  chemical  shift  scale  is  referenced  with
respect to the creatine signal (3.03 ppm).
It would be interesting to comparing the results of our in vivo MRS study with PET,
contrast enhanced MRI, radiation dose or the clinical outcome of the patients. However,
the outcome of the BNCT treatment of these patients is still under analysis, except for
patient 2. The promising treatment results of patient 2 have been presented previously
(Kouri et al 2004). However, we were not able to detect any characteristic BPA signals in
the brain spectra of patient 2.
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Figure 7  The aromatic region of the 3D 1H MR spectra measured from tumour (A) and
contralateral brain tissue (B) after BNCT in patient 9. In spectra A and B, baseline correction has
been applied. The same data without baseline correction is shown in spectra C and D for
comparison. Two signals can be detected in the tumour spectrum (A). The tumour (E) and
contralateral brain tissue (F) spectra measured one month after BNCT and spectra 3.0 mM BPA
aqueous solution (with 10.1mM creatine) (G) are also shown.
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Figure 8  The aromatic region of the 3D 1H MR spectra measured from tumour (A) and
contralateral brain tissue (B) during/after BPA-F infusion (MRSI data collection began 11 min
before and ended 6 min after the end of the infusion) in patient 10. The tumour (C) and
contralateral brain tissue spectra (D) measured four days before BNCT and spectra 3.0 mM BPA
aqueous solution (with 10.1mM creatine) (E) are also shown.
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Figure 9  The metabolite maps of patient 9. The metabolite maps are based on the Gaussian
lineshape fitting of two peaks detected in  the aromatic region after BNCT.
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Figure 10 The metabolite maps of patient 10 based on the Gaussian lineshape fitting of the
signal detected in the aromatic region during/immediately after BPA-F infusion.
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Figure 11 The metabolite region (0.5 - 4.2 ppm) of the 3D 1H MR spectra measured from the
tumour (above, left) and from the contralateral brain tissue (above, right) from patient 9 after
BNCT. Spectra from the tumour (below, left) and contralateral brain tissue (below, right) of
patient 10 measured during/immediately after BPA-F infusion are also shown.
Figure 12 3D 1H MRS spectra measured from 3.0 mM BPA aqueous solution (with 10.1mM
creatine) (A), the brain tumours of patients 9 (B) and 10 (C). Spectrum B was measured after
BNCT, and C during/directly after BPA-F infusion. Spectrum A appears in Figures 7 G  and 8 E,
spectrum B in Figure 7 A, and spectrum C in Figure 8 A.
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6. DISCUSSION
Our phantom studies show that proton magnetic resonance spectroscopy is a promising
method for detecting BPA-F in in vivo conditions.  Of  the  clinically  common 1H MRS
localisation  schemes  PRESS  and  STEAM,  the  PRESS  scheme  with  short  echo  time
(approximately 30 ms), was found to be optimal for detecting the aromatic protons of BPA
and achieves maximal signal-to-noise of the weak BPA aromatic signals in low BPA
concentrations. If quantification is needed, corrections for T2 relaxation are unnecessary if
a  short  TE  is  used.  Rather,  T1 corrections are needed, since TR is typically set to an
optimised value (approximately 1.3 x T1, too short to omit T1 effects) for maximal SNR.
The results of the in vitro phantom studies were promising. The outcome of the in vivo
MRS studies, however, was less satisfactory. Signals (SNR > 1) in the aromatic region of
the spectrum were detected in three of ten patients (patients 1, 9 and 10). For patient 9,
two distinct resonance lines were detected in the aromatic area (Figure 7 A), whereas for
patient 10, the corresponding resonance lines were broadened probably as a result of
poorer magnetic field homogeneity adjustments (i.e. shimming), and only a broad single
peak could be detected (Figure 8 A). The shape and position of the signals detected did not
exactly match the BPA spectrum detected under in vitro conditions, thus rendering
unambiguous assignment difficult (Figure 12). Possible explanations include changes in
the aromatic peak pattern in in vivo conditions due to some kind of dissociation of BPA-F
in the tissue environment and/or general chemical shift changes. Moreover, the low SNR
of the detected aromatic signals can lead to a situation where noise contribution can
change the expected multiplet pattern. Despite the unclear multiplet pattern, the aromatic
signals detected in the in vivo spectra obviously originate from BPA, since no detectable
signals in the aromatic area of the spectra were recorded during the treatment planning
MRI session (for patients 9 and 10) or one month after BNCT (patient 9).
The SNR of the detected in vivo signals was too low for quantification. BPA
concentrations in the brain were very close or below the in vivo detection limit of BPA.
Using the blood boron concentration determined during the MRS/MRSI measurements
and blood-to-tumour BPA concentration ratio 3.5, the estimated tumour BPA
concentration would exceed 3 mM for every patient. The BPA detection limit determined
in phantom conditions varied from 0.7 mM to 2.2 mM (Papers II and IV). Naturally, the
detection limit is notably higher under in vivo conditions due to more challenging
shimming environment. Bendel et al. (2005a) have extrapolated from high-field animal
studies that it would be possible to map concentrations of ? ~20 ppm boron from patients
in a clinical imager with about 1 cm3 spatial resolution. In water, 1 mM BPA equals 10
ppm 10B, but in blood or tissue, this number is only an approximation because the precise
relationship between the two concentration units depends on the tissue/blood density. The
blood boron concentration during MRS (Table 2) varied from 9 to 38 ppm (mg/kgwhole
blood). This indicates that the tumour boron concentration would be 31.5-133.0 ppm if the
blood-to-tumour concentration ratio would be the clinically proposed 1:3.5 during MRS.
Naturally, the concentration ratio could differ during the time of the MRS study from that
during the irradiation field (where a blood-to-tumour ratio of 1:3.5 is supposed).
According to an animal study by Wang et al. (2004), the tumour-to-blood and tumour-to-
39
healthy brain 10B concentration ratios for F98 glioma decrease as a function of time from
the maximum observed at 1 h post-injection. According to their study, two to four hours
after injection, the ratio would be about two. Using tumour-to-blood boron concentration
ratio of two, the boron concentration in the tumour would range from 18 to 50 ppm for
patients 1-9 during MRS. According to the estimated in vivo detection  limit,  even  those
concentrations should be detectable in vivo. However, the detected signals with low SNR
for three patients and the lack of detectable aromatic signals for the rest of the patients
suggest that the BPA concentration is even lower or the in vivo detection limit of BPA is
significantly higher than the previously estimated values. It is difficult to explain the
reason for the significantly higher detection limit of in vivo conditions as the spectrum
region from 1 to 4 ppm indicates normal quality (i.e. successful shimming, narrow lines)
(Figure 11). In addition, some have suggested that the in vivo MRS detection limit of the
lactate signal is ~1.5 mM (Dalsgaard et al. 2004). Obviously, it is difficult to directly
compare detection limits of the coupled lactate and coupled BPA aromatic protons signals.
In lactate, three protons produce the doublet detected at 1.33 ppm. In BPA, four protons
produce a “peak pattern” consisting of four main peaks (intensity ratio approx. 1:2:2:1).
However, this roughly translates to a ~1.7 mM detection limit of BPA, which is in line
with values estimated from phantom results.
The MRS results suggest that the previously estimated blood-to-tumour concentration
ratio of 1:3.5 is not necessarily valid during MRS. Alternatively, processes in the tumour
like possible binding of BPA to macromolecules or dissociation could, at least partially,
reduce it’s MRS visibly and lower its signal intensity. Bendel et al. (2005a, b) have
showed that dissociation from fructose complex to free BPA adds the additional peak
pattern to the spectrum. This may also broaden the BPA signal in the in vivo spectrum,
thus lowering the SNR and rising the detection limit of BPA. However, it was not possible
to determine which of these mechanisms was behind the low SNR of detected signals in
our study.
Several different methods and techniques have been used to determine the distribution
of BPA in the brain in vivo. PET with 18F BPA, prompt gamma spectroscopy (PGS),
microdialysis and spectroscopic methods including 1H, 11B/10B and 19F MRS offer
different  approaches  to  this  problem.  However,  all  of  these  methods  bear  their  own
limitations. The drawnback of PET is that 18F-labeled BPA is administrated as a bolus.
There is no clinical evidence whether the bolus data are sufficiently valid to evaluate the
tumour-to-brain concentration ratios (or absolute concentrations) obtained during the
actual two-hour BPA-F infusion. In PGS, various technical challenges remain unsolved.
Ideally, the detectors should be located in the irradiation room where they are prone to
neutron irradiation. The main problem of 11B/10B  MRS  is  the  lack  of 11B/10B detection
capabilities in clinical imagers. Neither 19F NMR is a standard feature in clinical
instruments. In addition, a separate infusion with a 11B-enriched carrier compound or the
use of 19F-labelled BPA is needed for 11B/19F spectroscopy/imaging. The 1H MRS of
BPA-F has many advantages: sensitivity of 1H detection, lack of spectral overlap and
availability in clinical scanners. In a study by Bergenheim et al. (2005), a microdialysis
method was applied to four patients who had received a 6-h BPA infusion. According to
that study, the maximal concentration ratio of the extracellular concentration of BPA in
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tumour tissue vs. blood was 1.07. Obviously, the intracellular concentration of boron
dominates BNCT. MRS cannot discriminate between intracellular and extracellular
spaces, but it can detect the concentration within the whole volume. The distribution of
brain tissue volume is ~85% intracellular and ~15% extracellular (Ross and Bluml 2001).
Consequently, comparing microdialysis results to the tumour boron concentration
measured by MRS is difficult.
The limitations of this study include its relatively low number of patients. In vivo
MRS/MRSI measurements of ten patients were performed during four years and two
months. Finding suitable patients for this study was difficult, since the tumour location
had to be suitable and its volume sufficient for MRSI. Furthermore, performing MRS until
an average of 3.5 hours after completion of the BPA infusion for patients (except for one)
proved impossible. The arrangement of MRS measurements during the BPA-F infusion
prior to BNCT was demanding. Patients had to be transferred from the MRI imager to the
BNCT facility for patient positioning and actual treatment immediately after MRS. From
the patient’s point of view, the day of BNCT was extremely exhausting even without MRS
measurements. This also raised some limitations with respect to the selection of patients
for MRS/MRSI. Also, the complicated shimming conditions due to resection cavities
(especially those containing blood) in operated tumours naturally makes boron detection
more challenging. The use of 3.0 T or even higher magnetic field MRS may improve the
feasibility of this method in clinical practice. In this study, 3.0 T 1H MRS was performed
for only one patient (patient 4), but detection of relevant signals in the aromatic area was
unsuccessful. Although increasing the magnetic field strength lowers the detection limit of
BPA in phantom conditions, and thus should improve the likelihood of detecting BPA in
vivo, challenges nevertless remain due to susceptibility effects when MRSI is performed in
the skull base area at high magnetic field.
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7. CONCLUSIONS
1. Under phantom conditions, BPA quantification accuracy of 5% can be achieved. BPA
can be quantified using either single voxel MRS or MRSI. Acquisition-weighted MRSI
allows the detection of low BPA concentrations in a reasonable measurement time.
2. The BPA detection limit in phantoms suggests that estimated typical in vivo tumour
BPA concentrations should lead to detectable signals.
3.  Detecting  BPA in vivo in a patient’s brain after a BNCT treatment or after the
completion of BPA infusion is possible. However, in vivo conditions pose many
challenges for BPA detection. In cases when clotted blood is present in the resection
cavity or when to tumour is located near air cavities (e.g. the paranasal sinuses)
susceptibility effects can disturb the MRS measurement. Unoperated tumours of relatively
large volume are optimal for MRS-based BPA-F detection. It is not possible to evaluate
the value of MRS for BNCT treatment planning from our data. The opportunity to perform
MRS immediately after the completion of BPA-F infusion for more patients will be
needed to evaluate the suitability of 1H MRS for BPA detection or quantification in BNCT
trials.
4. MRSI may provide criteria for selecting patients for BNCT. If no indicative signal is
detected from the volume of interest located in a region feasible for good quality MRS,
boron may not be accumulating sufficiently in the tumour to reach an appropriate radiation
dose level in BNCT.
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